Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988466 · ClinicalTrials.gov registry record · Phase 2
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT02988466: Completed Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT02988466 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 78 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02988466, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a single institution phase II study of a reduced intensity conditioning (RIC) followed by a haploidentical hematopoietic cell transplant (haplo-HCT) in persons with diagnosis of hematologic malignancy. Conditioning will consists of fludarabine, cyclophosphamide, melphalan and total body irradiation (TBI) preparative regimen with a melphalan dose reduction for patients ≥55 years old and those with HCT Comorbidity Index (CI) \>3. This study uses a two-stage phase II design with accrual goal of 84 patients, using 28 patients separately for arms A, C and D
Primary Outcome
Percentage of participants that were disease-free survival (DFS) at 1 year post-transplant
Interventions
- DRUG GVHD Prophylaxis
- BIOLOGICAL Haplo HCT <55 years old
- BIOLOGICAL Haplo HCT ≥55 years old
- BIOLOGICAL Haplo HCT ≥55 and < 65 years old
- BIOLOGICAL Haplo HCT ≥65 and ≤75 years old
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-01-24 |
| Est. Completion | 2025-03-24 |
| Phase | Phase 2 |
What the finished NCT02988466 record still lists
NCT02988466 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 5 interventions - of which GVHD Prophylaxis is the first listed.
NCT02988466 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02988466 about?
NCT02988466 is a clinical study titled "Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT". This is a single institution phase II study of a reduced intensity conditioning (RIC) followed by a haploidentical hematopoietic cell transplant (haplo-HCT) in persons with diagnosis of hematologic malignancy. Conditioning will consists of fludarabine, cyclophosphamide, melphalan and total body irra...
What is the current status of trial NCT02988466?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2017-01-24. Estimated completion is 2025-03-24.
What interventions are being tested in trial NCT02988466?
The interventions under investigation include: GVHD Prophylaxis (DRUG), Haplo HCT <55 years old (BIOLOGICAL), Haplo HCT ≥55 years old (BIOLOGICAL), Haplo HCT ≥55 and < 65 years old (BIOLOGICAL), Haplo HCT ≥65 and ≤75 years old (BIOLOGICAL).
Who is sponsoring clinical trial NCT02988466?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02988466's enrollment target sits among peer trials
78 884th of 2000 higher than 1,110 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI